exenatide once weekly + insulin detemir
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus
Trial Timeline
Oct 1, 2009 โ Dec 1, 2011
NCT ID
NCT01003184About exenatide once weekly + insulin detemir
exenatide once weekly + insulin detemir is a phase 3 stage product being developed by Eli Lilly for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT01003184. Target conditions include Type 2 Diabetes Mellitus.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01003184 | Phase 3 | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus